Regencell Bioscience Holdings Limited (RGC)
NEUTRALFundamental
66
Kurs
$5.55
Marktkapitalisierung
-
Teil 1 · Was das Unternehmen wert ist
Übersicht
Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Bilanz & Liquidität
Umsatz
$3.16B
Letzte 12 Monate (bis 31.12.2017)
Nettogewinn
$112M
Letzte 12 Monate (bis 31.12.2017)
Freier Cashflow
-
Gesamtes Eigenkapital
$-856M
Gesamtverbindlichkeiten
$3.70B
Current Ratio
0.83
Zinsdeckungsgrad
-
Schulden/EBITDA
-
Gewinn je Aktie
Umsatz & Nettogewinn
Freier Cashflow
Ertragsaufschlüsselung
Historische Aufstellung
Margen im Zeitverlauf
Verschuldung im Zeitverlauf
Wie schwer die Schulden wiegen
Wachstumsraster
Wachstum — Umsatz
Innerer-Wert-Schätzung
Innerer Wert
$3.74
Aktueller Kurs
$5.55
Sicherheitsmarge
-48.3%
Innerer-Wert-Spanne
$3.55 - $3.93
Bewertungsmethoden
Bewertungskennzahlen
P/E-Verhältnis
7.35
ROE
-13.1%
P/B-Verhältnis
-
P/FCF
-
Bruttomarge
-
ROIC
9.4%
Rentabilitäts-Radar
Value Creation (Economic Moat)
ROIC
9.4%
WACC
11.6%
ROIC − WACC
-2.2 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamentalanalyse-Kriterien
Bestanden (11)
- EPS shows upward trend
- EPS CAGR 18.50%
- Price CAGR 44.61%
- ROIC 9.4%
- Operating Margin 8.6%
- Current Ratio
- Return on Tangible Assets
- Low reliance on intangibles
- Earnings Quality (OCF/NI) 3.65
- Share Dilution -0.3%
- Piotroski F-Score 5/9
Nicht bestanden (3)
- DCF valuation (Unknown)
- ROE -231.9%
- Net Margin Trend 3.6% vs 5.3%
Nicht verfügbar (14)
- Gross Margin NaN%
- P/FCF NaN
- P/B Ratio NaN
- Dividend Payout NaN%
- Debt/Equity ratio
- Positive Free Cash Flow
- CapEx intensity
- Interest Coverage
- Debt/EBITDA
- Price below Graham Number
- Revenue Growth 5Y (Finnhub)
- Analyst Consensus (Finnhub)
- Earnings Surprise (Finnhub)
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-Score
Gemischte Signale: Einige Bereiche bedürfen Aufmerksamkeit
Gewinnqualität
Hohe Qualität: Gewinne durch Cashflow gedeckt
Aktienverwässerung
Aktienrückkäufe. Aktionärsfreundlich
Unternehmensführung
Führungsteam
| Name | Position | Alter |
|---|---|---|
| Mr. Yat-Gai Au | Founder, Chairman & CEO | 52 |
| Ms. Michelle Chan | Financial Controller, CFO & Principal Financial Officer | - |
| Mr. Wai Hong Chung | COO, Chief Strategy Officer & Director | 47 |
| Ms. Antonia Assang | Senior Vice President of Project Management | - |
| Mr. Yat-Pui Au | Chief Business Officer | 50 |
Teil 2 · Der Preis und der Einstiegszeitpunkt
Dieser Teil sagt nicht, ob das Unternehmen etwas taugt: Er hilft bei der Wahl des Kaufzeitpunkts, nachdem die Fundamentaldaten überzeugt haben. Enthalten: technische Analyse, Potenzial, historische Drawdowns, Gamma-Exposure.
Latest News
Recent headlines for RGC, sourced from Markets Gazette.
- 3/5/2026NEGATIVEDon't Even Think About Buying Regencell Bioscience Stock Until You See This 1 Red Flag
The article warns investors against buying Regencell Bioscience stock (RGC), highlighting a critical "red flag." While the company is exploring Traditional Chinese Medicine (TCM) opportunities, the exact nature and viability of these ventures remain unclear. This lack of transparency or concrete details regarding Regencell Bioscience's TCM strategies poses a significant risk. For investors, this indicates high uncertainty and potential undisclosed issues, making the stock unsuitable for speculative investment until operational details and market potential are clarified.
- 3/1/2026NEGATIVEForget Regencell Bioscience: This Blue Chip Drug Maker Is the Boring Compounder You Need
A recent financial analysis article advises investors to disregard general market sentiment concerning Regencell Bioscience Holdings Limited. While not providing specific details, the analysis casts the company in an unfavorable light, suggesting to "forget" it in favor of an unspecified blue-chip drug maker, described as a "boring compounder" that investors need. This implies a cautious or negative outlook on Regencell, suggesting its prospects might not be as promising as market perception, or that more solid, less volatile alternatives exist. Investors should consider this as a potential red flag, prompting further due diligence on the company before making investment decisions.
via Markets Gazette